anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Non-pulmonary vein (PV) triggers are increasingly targeted during atrial fibrillation (AF) ablation. P-wave morphology (PWM) can be useful because point mapping of AF triggers is challenging. The impact of prior ablation on PWM is yet to be determined.
OBJECTIVES: This study sought to report PWM before and after left atrial (LA) ablation and construct a P-wave algorithm of common non-PV trigger locations.
METHODS: This multicenter, prospective, observational study analyzed the paced PWM of 30 patients with persistent AF undergoing pulmonary vein isolation (PVI) and posterior wall isolation (PWI). Pace mapping was performed at the SVC, crista terminalis, inferior tricuspid annulus, coronary sinus ostium, left septum, left atrial appendage, Ligament of Marshall, and inferoposterior LA. The PWM was reported before PVI, then blinded comparisons were made post-PVI and post-PVI + PWI. A P-wave algorithm was constructed.
RESULTS: A total of 8,352 paced P waves were prospectively recorded. No significant changes in the PWM were seen post-PVI alone in 2,775 of 2,784 (99.7%) and post-PWI in 2,715 of 2,784 (97.5%). Changes in PWM were predominantly at the IPLA (53 P waves) with a positive P-wave in leads V2 to V6 before biphasic post-PWI, LA appendage (9 P waves), coronary sinus ostium (6 P waves), and ligament of Marshall (3 P waves). A PWM algorithm was created before PVI and accurately predicted the location in 93% post-PVI + PWI.
CONCLUSIONS: Minimal change was observed in PWM post-PV and PWI aside from the IPLA location. A P-wave algorithm created before and applied after PVI + PWI provided an accuracy of 93%. PWM provides a reliable tool to guide the localization of common non-PV trigger sites even after PV and PWI.
Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.
The percentage of patients in clinical studies for Effexor XR for MDD, GAD, SAD, and PD who were 65 years of age or older are shown in Table 16.

No overall differences in effectiveness or safety were observed between geriatric patients and younger patients, and other reported clinical experience generally has not identified differences in response between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. SSRIs and SNRIs, including Effexor XR, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions (5.9)].

The pharmacokinetics of venlafaxine and ODV are not substantially altered in the elderly [see Clinical Pharmacology (12.3)] (see Figure 1). No dose adjustment is recommended for the elderly on the basis of age alone, although other clinical circumstances, some of which may be more common in the elderly, such as renal or hepatic impairment, may warrant a dose reduction [see Dosage and Administration (2.8, 2.9)].
The present disclosure relates to the field of preventing or treating viral infections. In particular, the present disclosure relates to agents for vaccinating against viral infections and inducing potent viral antigen-specific immune responses (such as antibodies and/or T cell responses) and methods for producing and using these agents. Administration of an agent such as RNA disclosed herein to a subject can protect the subject from viral infection. In particular, the disclosure relates to amino acid sequences comprising at least a portion of a viral protein having amino acid modifications found in other variants of the viral protein. Administration of RNA encoding one or more amino acid sequences may provide protection against a variety of viral variants. In particular, the methods and agents described herein can be used to prevent or treat coronavirus infections, such as SARS-CoV-2 infection.
New N-thiopropionyl amino acid derivs. are cpds. of formula R4-S-CH2-CH-R3-CO-N-R2-CRR1-COOH (I) in which R and R1 are lower alkyl and R2 and R3 are H or lower alkyl, or R1 is linked with R or R2 so as to form a 5-membered ring; and R4 is H, lower alkanoyl or benzoyl. (I) are inhibitors of angiotensin converting enzyme and are useful in the treatment of hypertension, esp. angiotensin-induced hypertension. Specific cpds. (I) include 2- 3-(benzoylthio)propionamido -2-methylpropionic acid. In an example, this is prepd. by reacting alpha-aminoiosobutyric acid with 3-bromopropionyl chloride in the presence of NaOH, and reacting the product with thiobenzoic acid in the presence of K2CO3.
1443923 Delayed and sustained release compositions M SHEPARD 16 July 1973 [2 May 1972] 20412/72 Heading A5B Delayed release pharmaceutictal compositions in dosage unit form comprises two or more portions of pharmaceutically active material, each of which is individually provided with a retardant coating comprising a different water-insoluble normally solid fatty acid, each of the fatty acids having a melting point above body temperature and each fatty acid having a different melting point to the other(s). The fatty acid may be a saturated fatty acid such as lauric, myristic, stearic, behenic, lignoceric, palmitic or aracadic acid. The composition may also contain a portion of pharmaceutically active material having a coating of fatty acid having a melting point below body temperature i.e. capric acid. The composition may be in the form of granules which may be contained in a sachet or gelatine capsule, or compressed together with a tablet lubricant. The pharmaceutically active material may be selected from herbs, antihistamines, antibiotics, cardiovascular agents, central nervous system depressants, central nervous system stimulants, enzymes, gastrointestinal agents, haematological agents, immunological agents, hormones, renal acting and oedema reducing agents, nutrients and/or skeletal muscle relaxants.
Participants who were not previously included in any SAGE-718 clinical study. Participants will receive Sage-718 from Day 1 up to Month 48.
The scope and sequence of the standard diabetes self-management education (DSME) curriculum are aligned with national standards of the American Diabetes Association. DSME groups receive a 10-month intervention: 8 weekly educational sessions, followed by 8 bimonthly support group sessions, followed by 2 booster sessions.
Carbon nanomaterials possess antioxidant properties that can be applied in biomedicine and clinics for the development of new highly effective treatments against oxidative stress-induced diseases like ischemic heart disease. We previously reported the usage of graphene oxide (GrO) as a precursor for the elaboration of such prototypes. The promising findings led to the development of two new modifications of GrO: nitrogen-doped (N-GrO) and l-cysteine functionalized (S-GrO) derivatives as possible antioxidant agents in ischemia-reperfusion (I/R) conditions. In this study, the cardioprotective and antioxidant potential of modified GrO as a pre-treatment in rats was evaluated for the first time. In Langendorff isolated rat heart I/R model, the left ventricle developed pressure (LVDP), the end-diastolic pressure (EDP), the maximal (dP/dtmax) and minimal (dP/dtmin) value of the first derivative of LVDP, and heart rate (HR) were measured. The oxidative-nitrosative markers, in particular, the rate of O2*- and H2O2 generation, the content of malonic dialdehyde, diene conjugates, and leukotriene as well as cNOS and iNOS activity were estimated. Obtained results show a significant restoration of cadiodynamic parameters at the reperfusion period. Simultaneously, all samples significantly reduced the rate of reactive oxygen species (ROS) and lipid peroxidation markers in cardiac homogenates and preserved cNOS activity at the preischemic level. This evidence makes GrO derivatives promising candidates for the correction of reperfusion disorders affecting myocardial function.
Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg.
ABSTRACT     A   chemical   composition  for   electrolytic   transdermal transport. of  a  protein  to the blood  stream  of  the  patient comprises: a) a protein, b) a cosolvent with negative Setschenow constants, and c) water.    Some  of  the preferred  proteins  are:  insulin,  protamine sulfate, calcitonin, glucagon,  and  corticotropin.   Some of the preferred dissociating agents with negative Setschenow  constants are:  urea, propylurea, potassium iodide, sodium perchlorate, and guanidine hydrochloride.    The electrolytic  device containing the composition  to  be transdermally delivered comprises: two electrode elements separated by barrier means, a   reservoir  containing  the  composition  of  the invention, an   electronic/electrolytic  circuit  including   a source of a power, a cover, and adhesive  means holding the device to the  patient's skin. A semipermeable membrane between the patient's skin and  the electrolytic device is optional.
Subjects assigned to Arm 1 will be instructed to shower daily beginning on post-operative Day 2 and maintain this daily schedule until the subject's 3-month standard of care clinic follow-up visit. They will receive specific instructions on caring for the incision site and drains until they are removed.
Foodstuff contg. vitamin K and iron and fluorine cpds. for attaining anti-caries activity characterised in that: (a) it contains vitamin K in an amt. effective for the redn. of caries; (b) it contains one or more iron cpds. in an amt. of from 1-1000 mg per 100 g of dry matter, assisting the caries resisting effect of the vitamin K; (c) it contains fluorine cpd. which provides from 0.001-0.75 mg of available fluorine per 100 g of dry matter; (d) the iron and vitamin K are wholly or partly incorporated in a component of the foodstuff which component possesses the adherence to the teeth of cheese. - (12pp) EPAB- EP-117321 B Foodstuff contg. vitamin K and iron and fluorine cpds. for attaining anti-caries activity characterised in that: (a) it contains vitamin K in an amt. effective for the redn. of caries; (b) it contains one or more iron cpds. in an amt. of from 1-1000 mg per 100 g of dry matter, assisting the caries resisting effect of the vitamin K; (c) it contains fluorine cpd. which provides from 0.001-0.75 mg of available fluorine per 100 g of dry matter; (d) the iron and vitamin K are wholly or partly incorporated in a component of the foodstuff which component possesses the adherence to the teeth of cheese.
Three stimulation points were selected for each ear of tinnitus patients, namely ear door (CN.V), auditory Palace (CN.VII) and Yifeng (C2/3). The stimulation intensity should be needle-sensed.
Ribosomal DNA (rDNA) copies exist across multiple chromosomes, and interindividual variation in copy number is speculated to influence the hypertrophic response to resistance training. Thus, we examined if rDNA copy number was associated with resistance training-induced skeletal muscle hypertrophy. Participants (n = 53 male, 21 ± 1 yr old; n = 29 female, 21 ± 2 yr old) performed 10-12 wk of full-body resistance training. Hypertrophy outcomes were determined, as was relative rDNA copy number from preintervention vastus lateralis (VL) biopsies. Pre- and postintervention VL biopsy total RNA was assayed in all participants, and mRNA/rRNA markers of ribosome content and biogenesis were also assayed in the 29 female participants before training, 24 h following training bout 1, and in the basal state after 10 wk of training. Across all participants, no significant associations were evident between relative rDNA copy number and training-induced changes in whole body lean mass (r = -0.034, P = 0.764), vastus lateralis thickness (r = 0.093, P = 0.408), mean myofiber cross-sectional area (r = -0.128, P = 0.259), or changes in muscle RNA concentrations (r = 0.026, P = 0.818), and these trends were similar when examining each gender. However, all Pol-I regulon mRNAs as well as 45S pre-rRNA, 28S rRNA, and 18S rRNA increased 24 h following the first training bout in female participants. Follow-up studies using LHCN-M2 myotubes demonstrated that a reduction in relative rDNA copy number induced by bisphenol A did not significantly affect insulin-like-growth factor-induced myotube hypertrophy. These findings suggest that relative rDNA copy number is not associated with myofiber hypertrophy.NEW & NOTEWORTHY We examined ribosomal DNA (rDNA) copy numbers in men and women who resistance trained for 10-12 wk and found no significant associations with skeletal muscle hypertrophy outcomes. These data, along with in vitro data in immortalized human myotubes whereby rDNA copy number was reduced, provide strong evidence that relative rDNA copy number is not associated with anabolism.
A total of 52 primary schools were screened comprehensively to determine children conforming specifications of the inclusion criteria. Demographic characteristics (e.g. age, gender, affected side) and severity of functional impairment dealing with cognitive /communication, manual ability and mobility were noted. After a comprehensive screening, a total of 30 children met inclusion criteria (grades 1-4) were randomly assigned to one of two groups (Modified Constraint-Induced Movement Therapy or Bimanual training), at an equal number and probability. Children blinded to group allocation were delivered activity-based upper limb training in the context of Modified Constraint-Induced Movement Therapy or Bimanual training, at a similar dose and frequency (10 weeks/3 days per week/2.5 hours per day). 1 out of 3 sessions per week was carried out in the school time (during the art or physical education class), while 2 out of 3 sessions were carried out in rehabilitation centers which the children regularly attend for regular care 2-day weekly. All participating children continued to receive their standard care (90 minutes per week) throughout the study period.

During the 1-month screening period, physical characteristics of participants were described through classification systems including The Communication Function Classification System, The Manual Ability Classification System , and The Gross Motor Function Classification System. Participating children were evaluated before the study entry (T1), immediately postintervention (T2), and at 16 weeks postintervention (T3) using the KIDSCREEN-27 questionnaire
Patients receive pembrolizumab IV over 30 minutes, bevacizumab IV over 30-90 minutes, and CDX-1140 IV over 90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity.
BACKGROUND: Biologics are effective for chronic rhinosinusitis with nasal polyposis (CRSwNP) by reducing type 2 inflammation. Nonresponders often require functional endoscopic sinus surgery (FESS) and represent a challenging population potentially due to non-type 2 pathophysiology. This study characterizes the histopathologic features of biologic nonresponders.
METHODS: A retrospective review of 257 CRSwNP patients undergoing FESS was conducted. The biologic nonresponder group included patients with prior biologic therapy who exhibited persistent symptoms and polyp burden. Those with CRSwNP not prescribed biologic therapy were selected as controls. Demographics, comorbidities, and structured histopathology consisting of 13 variables were collected.
RESULTS: Of 257 CRSwNP patients, 20 were on biologics prior to FESS. Fourteen patients (70.0%) received dupilumab, one (5.0%) received mepolizumab, one (5.0%) received omalizumab, and four (20.0%) tried multiple biologics. The mean age for the biologic nonresponder group was 45.8 years compared to 50.4 years for the controls. Nonresponders had a significantly increased incidence of reduced tissue eosinophilia, defined as <5 per high power field (55% vs. 31.2%, p = 0.044) and increased basement membrane thickening (100% vs. 78.1%, p = 0.019). The remaining 11 variables did not reach statistical significance.
CONCLUSION: Histopathologic analysis of biologic nonresponders demonstrates decreased eosinophilia and thickened basement membranes. These findings, particularly low tissue eosinophils, are consistent with a non-type 2 CRSwNP that may be recalcitrant to biologic therapies. Histopathologic analysis done in conjunction with FESS may aid clinicians in understanding response to biologic therapies in patients with CRSwNP who have persistent symptom burden necessitating FESS.
This study was conducted in Hufash district, Al-Mahweet Province, which is located on the southwest of the capital Sana'a, and takes about (113)kilometers from it. The study aimed to highlight the key role of the community based interventions in reducing child morbidity and mortality in rural Yemen.A community - randomized controlled field trail was implemented to evaluate the role of public health promotion on reducing child diarrhea, acute respiratory infection, nutrition, immunization in children under age of five at enrollment over a six month of study period. Due to the nature of the study, blinding is not possible so some measures would be done to reduce the non-blinding bias like, to keep the study staff blinded as much as possible, the observers and survey staff were not informed about the study design. The sample size required to measure the primary and secondary outcomes before and after the intervention in both groups was estimated using STATA 14.0.Based on data of a previous meta analysis, estimates of required sample size assumed a 20% reduction in the proportion of diarrhea. Intra-cluster correlation coefficient (ICC) was set low at 0.04 and the cluster sizes (number of subjects in a cluster, m) were expected to be 18. The sample size was multiplied by a design effect of 1.68, calculated using DE=1+ICC (m-1), to accommodate the clustering effect. The sample was further adjusted for a potential 20% loss to follow-up over one year, thus requiring a sample of 180 per group. Therefore, the present study estimated that a total of 20 clusters inhabited by 358 households with child aged 6 to 59 months would have 80% power to detect the 20% reduction in the proportion in diarrhea at 5% level of significance.
OBJECTIVE: To quantify the risk of adverse postoperative outcomes in pediatric patients with COVID-19 infection.
METHODS: We searched PubMed, Embase, Cochrane Library from December 2019 to 21 April 2023. Observational cohort studies that reported postoperative early mortality and pulmonary complications of pediatric patients with confirmed COVID-19-positive compared with COVID-19-negative were eligible for inclusion. We excluded pediatric patients underwent organ transplantation or cardiac surgery. Reviews, case reports, letters, and editorials were also excluded. We used the Newcastle-Ottawa Scale to assess the methodological quality and risk of bias for each included study. The primary outcome was postoperative early mortality, defined as mortality within 30 days after surgery or during hospitalization. The random-effects model was performed to assess the pooled estimates, which were expressed as risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI).
RESULTS: 9 studies involving 23,031 pediatric patients were included, and all studies were rated as high quality. Compared with pediatric patients without COVID-19, pediatric patients with COVID-19 showed a significantly increased risk of postoperative pulmonary complications (PPCs) (RR = 4.24; 95% CI 2.08-8.64). No clear evidence was found for differences in postoperative early mortality (RR = 0.84; 95% CI 0.34-2.06), postoperative intensive care unit (ICU) admission (RR = 0.80; 95% CI 0.39-1.68), and length of hospital stay (MD = 0.35, 95% CI -1.81-2.51) between pediatric patients with and without COVID-19.
CONCLUSION: Perioperative COVID-19 infection was strongly associated with increased risk of PPCs, but it did not increase the risk of postoperative early mortality, the rate of postoperative ICU admission, and the length of hospital stay in pediatric patients. Our preplanned sensitivity analyses confirmed the robustness of our study findings.
To provide a set of an artificial nail chip for nail and a curable composition for preventing unnecessary damage applied to a nail.SOLUTION: A nail chip curable composition comprises: an extend gel; an edge-off flat brush; a nail file; a plurality of Gel-X chips; a pH bonder; and a non-acid gel primer. The pH bonder forms a pH bonder layer on a surface of a nail. The non-acid gel primer forms a non-acid gel primer layer so as to be overlapped to the pH bonder layer. The extend gel forms an extend gel layer so as to be overlapped to the non-acid gel primer layer. The Gel-X chip is filed by a nail file, then the extend gel is applied to a lower side contact surface of the Gel-X chip by the edge-off flat brush. In a state in which the Gel-X chip is firmly stuck to the nail, the lower side contact surface of the Gel-X chip is brought into contact with the extend gel layer on the nail.SELECTED DRAWING: None
PROBLEM TO BE SOLVED: To obtain the subject pharmaceutical preparation comprising a substance having mild arterialization-inhibiting action usable for a long period and useful for preventing metastasis and relapse of cancer. SOLUTION: This pharmaceutical preparation comprises a substance having preventing action on arterialization, e.g. a fumagiol derivative represented by the formula (R<1> is a hydrocarbon; R<2> is a hydrocarbon or an acyl) or its salt. The fumagiol derivative or its salt is produced as a pharmaceutically permissible acid addition salt when the compound of the formula contains a basic salt and it is produced as a salt with similar base when the compound of the formula contain an acidic group. The compound of the formula is effective in treating and preventing various kinds of diseases such as tumor and the active amount is usually about 0.1-100wt.% based on total amount of preparation. The preparation is prepared in a tablet, fine particles, etc., according to an ordinary method.
Sarcopenic obesity (SO) is characterized by concomitant sarcopenia and obesity and presents a high risk of disability, morbidity, and mortality among older adults. However, predictions based on sequential neural network SO studies and the relationship between physical fitness factors and SO are lacking. This study aimed to develop a predictive model for SO in older adults by focusing on physical fitness factors. A comprehensive dataset of older Korean adults participating in national fitness programs was analyzed using sequential neural networks. Appendicular skeletal muscle/body weight was defined as SO using an anthropometric equation. Independent variables included body fat (BF, %), waist circumference, systolic and diastolic blood pressure, and various physical fitness factors. The dependent variable was a binary outcome (possible SO vs normal). We analyzed hyperparameter tuning and stratified K-fold validation to optimize a predictive model. The prevalence of SO was significantly higher in women (13.81%) than in men, highlighting sex-specific differences. The optimized neural network model and Shapley Additive Explanations analysis demonstrated a high validation accuracy of 93.1%, with BF% and absolute grip strength emerging as the most influential predictors of SO. This study presents a highly accurate predictive model for SO in older adults, emphasizing the critical roles of BF% and absolute grip strength. We identified BF, absolute grip strength, and sit-and-reach as key SO predictors. Our findings underscore the sex-specific nature of SO and the importance of physical fitness factors in its prediction.